The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients ...

The research team led by Senior Researchers Yoonhee Lee from the Division of Biomedical Technology and Gyogwon Koo from the ...

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer ...

While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for ...

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

The drug is being developed for the treatment of small cell lung cancer and neuroendocrine carcinoma, including neuroendocrine prostate cancer. The multi-center, first-in-human, open-label, phase 2/3 ...